Lumida
/DSGN
⌘K
Design Therapeutics Inc

Design Therapeutics Inc

DSGN
$14.63USD↓-1.15%-0.17 today

MARKET CAP

915.6M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$14 – $15

52W RANGE

$5
$17

AI Summary

Stalk
Buy NowHigh

In a Stage 2 advancing corrective reset within a broader uptrend, active Lockout Rally dynamics and sustained EMA support justify immediate bullish participation despite overbought readings, focusing on pullbacks into rising EMA confluence near the prior breakout zone.

  • ↑Phase 1 MAD trial raised frataxin mRNA by 30% at 300 mg vs placebo.
  • ↑Ended Q2 2023 with $303 M cash, funding ops through 2026.
  • ↓Earnings yield and profitability scores deeply negative, signaling poor returns.
Full analysis →
Insider Trades0 trades
No trades match the current filters